Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.50 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 12/20 | 0.43 |
| ▸ | RIPK3 | Q9Y572 | 3/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640833 | 0.80 | RIPK2 (0.52) | RIPK2RIPK3RIPK1EGFRKDR | |
| SCHEMBL1643065 | 0.77 | KMT2A (0.59) | CDK2 | |
| SCHEMBL13663570 | 0.77 | JAK2 (0.46) | TRPM5RIPK2RIPK3EGFRKDR | |
| SCHEMBL2885798 | 0.71 | CDK2 (0.73) | CDK2EGFRKDR | |
| SCHEMBL24588180 | 0.70 | RIPK2 (0.56) | TRPM5HSD11B1RIPK2RIPK3RIPK1 | |
| SCHEMBL1121971 | 0.69 | CDK2 (0.70) | CDK2EGFRKDR | |
| SCHEMBL30574121 | 0.69 | MAPT (0.62) | CDK2 | |
| SCHEMBL6661698 | 0.68 | CDK2 (0.69) | CDK2SYK | |
| SCHEMBL6302354 | 0.68 | CDK2 (0.69) | CDK2EGFRKDR | |
| SCHEMBL10077411 | 0.68 | HSD11B1 (0.50) | TRPM5HSD11B1RIPK2RIPK3RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| EP-2252597-A2 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | Akinion Pharmaceuticals AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | CDK2 93/4885TRPM5 1462/4885HSD11B1 3571/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | CDK2 93/4885TRPM5 1462/4885HSD11B1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.